{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:40:24Z","timestamp":1774266024235,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-Young2023-0114"],"award-info":[{"award-number":["Y-Young2023-0114"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To evaluate the efficacy and safety of nab-paclitaxel plus cisplatin as the regimen of conversional chemoradiotherapy (cCRT) in locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma (ESCC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with locally advanced ESCC (cT3\u20114, Nany, M0\u20111, M1 was limited to lymph node metastasis in the supraclavicular area) were enrolled. All the patients received the cCRT of nab-paclitaxel plus cisplatin. After the cCRT, those resectable patients received esophagectomy; those unresectable patients continued to receive the definitive chemoradiotherapy (dCRT). The locoregional control (LRC), overall survival (OS), event-free survival (EFS), distant metastasis free survival (DMFS), pathological complete response (pCR), R0\u00a0resection rate, adverse events (AEs) and postoperative complications were calculated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>45\u00a0patients with ESCC treated from October 2019 to May 2021 were finally included. The median follow-up time was 30.3 months. The LRC, OS, EFS, DMFS at 1\u00a0and 2\u00a0years were 81.5%, 86.6%, 64.3%, 73.2 and 72.4%, 68.8%, 44.8%, 52.7% respectively. 21\u00a0patients (46.7%) received conversional chemoradiotherapy plus surgery (cCRT+S). The pCR rate and R0\u00a0resection rate were 47.6 and 84.0%. The LRC rate at 1\u00a0and 2\u00a0years were 95.0%, 87.1% in cCRT+S\u00a0patitents and 69.3%, 58.7% in dCRT patients respectively (HR, 5.14; 95%CI, 1.10\u201323.94; <jats:italic>P<\/jats:italic>\u202f=\u20090.021). The toxicities during chemoradiotherapy were tolerated, and the most common grade\u00a03\u20134 toxicitiy was radiation esophagitis (15.6%). The most common postoperative complication was pleural effusion (38.1%) and no grade\u202f\u2265\u2009IIIb complications were observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>nab-paclitaxel plus cisplatin are safe as the regimen of conversional chemoradiotherapy of ESCC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-024-02286-8","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T19:02:06Z","timestamp":1723489326000},"page":"1038-1046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase\u00a0i\/ii prospective cohort study"],"prefix":"10.1007","volume":"200","author":[{"given":"Nuo","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiankai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozheng","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guojie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinfu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jima","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zefen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"2286_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung\u00a0H, Ferlay\u00a0J, Siegel\u00a0RL, Laversanne\u00a0M, Soerjomataram\u00a0I, Jemal\u00a0A et\u00a0al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"2286_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.20892\/j.issn.2095-3941.2016.0093","volume":"14","author":"H Liang","year":"2017","unstructured":"Liang\u00a0H, Fan\u00a0JH, Qiao\u00a0YL (2017) Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol Med 14:33\u201341. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2016.0093","journal-title":"Cancer Biol Med"},{"key":"2286_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10388-021-00864-8","volume":"19","author":"Z Wang","year":"2022","unstructured":"Wang\u00a0Z, Hu\u00a0M, Hu\u00a0Y, Li\u00a0Q, Wu\u00a0J, Fong\u00a0WP et\u00a0al (2022) Paclitaxel plus cisplatin and 5\u2011fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a\u00a0phase\u00a0II clinical trial. Esophagus 19:120\u2013128. https:\/\/doi.org\/10.1007\/s10388-021-00864-8","journal-title":"Esophagus"},{"key":"2286_CR4","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1245\/s10434-019-08124-x","volume":"27","author":"T Suzuki","year":"2020","unstructured":"Suzuki\u00a0T, Okamura\u00a0A, Watanabe\u00a0M, Mine\u00a0S, Imamura\u00a0Y, Asari\u00a0T et\u00a0al (2020) Neoadjuvant chemoradiotherapy with cisplatin plus fluorouracil for borderline resectable esophageal squamous cell carcinoma. Ann Surg Oncol 27:1510\u20131517. https:\/\/doi.org\/10.1245\/s10434-019-08124-x","journal-title":"Ann Surg Oncol"},{"key":"2286_CR5","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1007\/s00268-019-05000-3","volume":"43","author":"M Takeuchi","year":"2019","unstructured":"Takeuchi\u00a0M, Kawakubo\u00a0H, Mayanagi\u00a0S, Yoshida\u00a0K, Irino\u00a0T, Fukuda\u00a0K et\u00a0al (2019) The benefits of docetaxel plus cisplatin and 5\u2011fluorouracil induction therapy in conversion to curative treatment for locally advanced esophageal squamous cell carcinoma. World J Surg 43:2006\u20132015. https:\/\/doi.org\/10.1007\/s00268-019-05000-3","journal-title":"World J Surg"},{"key":"2286_CR6","doi-asserted-by":"publisher","first-page":"935374","DOI":"10.3389\/fimmu.2022.935374","volume":"13","author":"S Huang","year":"2022","unstructured":"Huang\u00a0S, Wu\u00a0H, Cheng\u00a0C, Zhou\u00a0M, Xu\u00a0E, Lin\u00a0W et\u00a0al (2022) Conversion surgery following Immunochemotherapy in initially unresectable locally advanced esophageal squamous cell carcinoma\u2011a real-world multicenter study (RICE-retro). Front Immunol 13:935374. https:\/\/doi.org\/10.3389\/fimmu.2022.935374","journal-title":"Front Immunol"},{"key":"2286_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","volume":"170","author":"DA Yardley","year":"2013","unstructured":"Yardley\u00a0DA (2013) nab-Paclitaxel mechanisms of action and delivery. J\u00a0Control Release 170:365\u2013372. https:\/\/doi.org\/10.1016\/j.jconrel.2013.05.041","journal-title":"J Control Release"},{"key":"2286_CR8","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.2147\/OTT.S108580","volume":"9","author":"HY Wang","year":"2016","unstructured":"Wang\u00a0HY, Yao\u00a0ZH, Tang\u00a0H, Zhao\u00a0Y, Zhang\u00a0XS, Yao\u00a0SN et\u00a0al (2016) Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma. Onco Targets Ther 9:5663\u20135669. https:\/\/doi.org\/10.2147\/OTT.S108580","journal-title":"Onco Targets Ther"},{"key":"2286_CR9","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.2147\/OTT.S168275","volume":"11","author":"D Wang","year":"2018","unstructured":"Wang\u00a0D, Zhang\u00a0W, Qian\u00a0D, Guan\u00a0Y, Chen\u00a0X, Zhang\u00a0H et\u00a0al (2018) Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a\u00a0pilot trial. Onco Targets Ther 11:6333\u20136338. https:\/\/doi.org\/10.2147\/OTT.S168275","journal-title":"Onco Targets Ther"},{"key":"2286_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004291","author":"J Liu","year":"2022","unstructured":"Liu\u00a0J, Yang\u00a0Y, Liu\u00a0Z, Fu\u00a0X, Cai\u00a0X, Li\u00a0H et\u00a0al (2022) Multicenter, single-arm, phase\u00a0II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J\u00a0Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-004291","journal-title":"J Immunother Cancer"},{"key":"2286_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1148\/radiology.146.2.6849089","volume":"146","author":"D Picus","year":"1983","unstructured":"Picus\u00a0D, Balfe\u00a0DM, Koehler\u00a0RE, Roper\u00a0CL, Owen\u00a0JW (1983) Computed tomography in the staging of esophageal carcinoma. Radiology 146:433\u2013438. https:\/\/doi.org\/10.1148\/radiology.146.2.6849089","journal-title":"Radiology"},{"key":"2286_CR12","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1001\/jamaoncol.2019.2809","volume":"5","author":"D Chen","year":"2019","unstructured":"Chen\u00a0D, Menon\u00a0H, Verma\u00a0V, Seyedin\u00a0SN, Ajani\u00a0JA, Hofstetter\u00a0WL et\u00a0al (2019) Results of a\u00a0phase\u00a01\/2 trial of chemoradiotherapy with simultaneous integrated boost of radiotherapy dose in unresectable locally advanced esophageal cancer. JAMA Oncol 5:1597\u20131604. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2809","journal-title":"JAMA Oncol"},{"key":"2286_CR13","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-07-4592","volume":"14","author":"ER Gardner","year":"2008","unstructured":"Gardner\u00a0ER, Dahut\u00a0WL, Scripture\u00a0CD, Jones\u00a0J, Aragon-Ching\u00a0JB, Desai\u00a0N et\u00a0al (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14:4200\u20134205. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4592","journal-title":"Clin Cancer Res"},{"key":"2286_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","volume":"65","author":"H Maeda","year":"2013","unstructured":"Maeda\u00a0H, Nakamura\u00a0H, Fang\u00a0J (2013) The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65:71\u201379. https:\/\/doi.org\/10.1016\/j.addr.2012.10.002","journal-title":"Adv Drug Deliv Rev"},{"key":"2286_CR15","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","volume":"281","author":"JS Cooper","year":"1999","unstructured":"Cooper\u00a0JS, Guo\u00a0MD, Herskovic\u00a0A, Macdonald\u00a0JS, Martenson\u00a0JA Jr, Al-Sarraf\u00a0M et\u00a0al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a\u00a0prospective randomized trial (RTOG 85\u201301). Radiation therapy oncology group. JAMA 281:1623\u20131627. https:\/\/doi.org\/10.1001\/jama.281.17.1623","journal-title":"JAMA"},{"key":"2286_CR16","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen\u00a0P, Hulshof\u00a0MC, van Lanschot\u00a0JJ, Steyerberg\u00a0EW, van Berge Henegouwen\u00a0MI, Wijnhoven\u00a0BP et\u00a0al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N\u00a0Engl J Med 366:2074\u20132084. https:\/\/doi.org\/10.1056\/NEJMoa1112088","journal-title":"N Engl J Med"},{"key":"2286_CR17","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1200\/JCO.18.02122","volume":"37","author":"Y Chen","year":"2019","unstructured":"Chen\u00a0Y, Ye\u00a0J, Zhu\u00a0Z, Zhao\u00a0W, Zhou\u00a0J, Wu\u00a0C et\u00a0al (2019) Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: a\u00a0randomized, multicenter, phase\u00a0III clinical trial. J\u00a0Clin Oncol 37:1695\u20131703. https:\/\/doi.org\/10.1200\/JCO.18.02122","journal-title":"J Clin Oncol"},{"key":"2286_CR18","doi-asserted-by":"publisher","first-page":"e220120","DOI":"10.1001\/jamanetworkopen.2022.0120","volume":"5","author":"D Ai","year":"2022","unstructured":"Ai\u00a0D, Ye\u00a0J, Wei\u00a0S, Li\u00a0Y, Luo\u00a0H, Cao\u00a0J et\u00a0al (2022) Comparison of 3 paclitaxel-based chemoradiotherapy regimens for patients with locally advanced esophageal squamous cell cancer: a\u00a0randomized clinical trial. JAMA Netw Open 5:e220120. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.0120","journal-title":"JAMA Netw Open"},{"issue":"10447","key":"2286_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato\u00a0K, Machida\u00a0R, Ito\u00a0Y, Daiko\u00a0H, Ozawa\u00a0S, Ogata\u00a0T et\u00a0al (2024) Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a\u00a0randomised, controlled, open-label, phase\u00a03\u00a0trial. Lancet 404(10447):55\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(24)00745-1","journal-title":"Lancet"},{"issue":"5","key":"2286_CR20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1001\/jamasurg.2021.0133","volume":"156","author":"H Wang","year":"2021","unstructured":"Wang\u00a0H, Tang\u00a0H, Fang\u00a0Y, Tan\u00a0L, Yin\u00a0J, Shen\u00a0Y et\u00a0al (2021) Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: a\u00a0randomized clinical trial. JAMA Surg 156(5):444\u2013451. https:\/\/doi.org\/10.1001\/jamasurg.2021.0133","journal-title":"JAMA Surg"},{"key":"2286_CR21","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","volume":"36","author":"H Yang","year":"2018","unstructured":"Yang\u00a0H, Liu\u00a0H, Chen\u00a0Y, Zhu\u00a0C, Fang\u00a0W, Yu\u00a0Z et\u00a0al (2018) Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a\u00a0phase\u00a0III multicenter, randomized, open-label clinical trial. J\u00a0Clin Oncol 36:2796\u20132803. https:\/\/doi.org\/10.1200\/JCO.2018.79.1483","journal-title":"J Clin Oncol"},{"key":"2286_CR22","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1097\/SLA.0000000000004564","volume":"274","author":"K Sugimura","year":"2021","unstructured":"Sugimura\u00a0K, Miyata\u00a0H, Tanaka\u00a0K, Makino\u00a0T, Takeno\u00a0A, Shiraishi\u00a0O et\u00a0al (2021) Multicenter randomized phase\u00a02 trial comparing chemoradiotherapy and docetaxel plus 5\u2011fluorouracil and cisplatin chemotherapy as initial induction therapy for subsequent conversion surgery in patients with clinical T4b esophageal cancer: short-term results. Ann Surg 274:e465\u2013e472. https:\/\/doi.org\/10.1097\/SLA.0000000000004564","journal-title":"Ann Surg"},{"key":"2286_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1245\/s10434-020-08865-0","volume":"28","author":"T Abe","year":"2021","unstructured":"Abe\u00a0T, Higaki\u00a0E, Hosoi\u00a0T, Nagao\u00a0T, Bando\u00a0H, Kadowaki\u00a0S et\u00a0al (2021) Long-term outcome of patients with locally advanced clinically unresectable esophageal cancer undergoing conversion surgery after induction chemotherapy with docetaxel plus cisplatin and 5\u2011fluorouracil. Ann Surg Oncol 28:712\u2013721. https:\/\/doi.org\/10.1245\/s10434-020-08865-0","journal-title":"Ann Surg Oncol"},{"key":"2286_CR24","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/cncr.26586","volume":"118","author":"J Welsh","year":"2012","unstructured":"Welsh\u00a0J, Settle\u00a0SH, Amini\u00a0A, Xiao\u00a0L, Suzuki\u00a0A, Hayashi\u00a0Y et\u00a0al (2012) Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 118:2632\u20132640. https:\/\/doi.org\/10.1002\/cncr.26586","journal-title":"Cancer"},{"key":"2286_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.radonc.2017.06.019","volume":"124","author":"M Xi","year":"2017","unstructured":"Xi\u00a0M, Xu\u00a0C, Liao\u00a0Z, Hofstetter\u00a0WL, Blum\u00a0MM, Maru\u00a0DM et\u00a0al (2017) The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol 124:318\u2013324. https:\/\/doi.org\/10.1016\/j.radonc.2017.06.019","journal-title":"Radiother Oncol"},{"key":"2286_CR26","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.ijrobp.2004.05.056","volume":"60","author":"Z Liao","year":"2004","unstructured":"Liao\u00a0Z, Zhang\u00a0Z, Jin\u00a0J, Ajani\u00a0JA, Swisher\u00a0SG, Stevens\u00a0CW et\u00a0al (2004) Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage\u00a0II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys 60:1484\u20131493. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.05.056","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2286_CR27","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1245\/s10434-019-07727-8","volume":"26","author":"H Miyata","year":"2019","unstructured":"Miyata\u00a0H, Sugimura\u00a0K, Motoori\u00a0M, Omori\u00a0T, Yamamoto\u00a0K, Yanagimoto\u00a0Y et\u00a0al (2019) Clinical implications of conversion surgery after induction therapy for T4b thoracic esophageal squamous cell carcinoma. Ann Surg Oncol 26:4737\u20134743. https:\/\/doi.org\/10.1245\/s10434-019-07727-8","journal-title":"Ann Surg Oncol"},{"key":"2286_CR28","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun\u00a0JM, Shen\u00a0L, Shah\u00a0MA, Enzinger\u00a0P, Adenis\u00a0A, Doi\u00a0T et\u00a0al (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a\u00a0randomised, placebo-controlled, phase\u00a03\u00a0study. Lancet 398:759\u2013771. https:\/\/doi.org\/10.1016\/S0140-6736(21)01234-4","journal-title":"Lancet"},{"key":"2286_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","volume":"144","author":"C Li","year":"2021","unstructured":"Li\u00a0C, Zhao\u00a0S, Zheng\u00a0Y, Han\u00a0Y, Chen\u00a0X, Cheng\u00a0Z et\u00a0al (2021) Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J Cancer 144:232\u2013241. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.039","journal-title":"Eur J Cancer"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02286-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-024-02286-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02286-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T13:02:33Z","timestamp":1732539753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-024-02286-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2286"],"URL":"https:\/\/doi.org\/10.1007\/s00066-024-02286-8","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.\u00a0Yu, X.\u00a0Chen, J.\u00a0Li, X.\u00a0Kang, Z.\u00a0Wang, R.\u00a0Zhang, J.\u00a0Qin, Y.\u00a0Li, Q.\u00a0Zheng, G.\u00a0Feng, L.\u00a0Deng, T.\u00a0Zhang, W.\u00a0Wang, W.\u00a0Liu, J.\u00a0Wang, Q.\u00a0Feng, J.\u00a0Lv, Z.\u00a0Zhou, Z.\u00a0Xiao, N.\u00a0Bi, Y.\u00a0Li and X.\u00a0Wang declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Information of this clinical trial: This trial has been aprroved by the Ethics Committee of National Cancer Center. The file number is 19\/325-2109 and the registration number at clinicaltrials.gov is NCT04278287. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}